Krka d.d. | Income Statement

Fiscal year is January-December. All values EUR Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
1,201
1,192
1,165
1,174
1,266
1,332
Cost of Goods Sold (COGS) incl. D&A
489
470
490
548
539
561
Gross Income
712
721
675
627
728
771
SG&A Expense
487
489
498
509
530
548
EBIT
224
232
177
119
198
225
Unusual Expense
-
40
31
48
8
-
Non Operating Income/Expense
24
95
27
44
30
21
Interest Expense
-
3
2
-
-
3
Pretax Income
201
175
181
116
176
203
Income Tax
29
9
23
8
24
29
Consolidated Net Income
173
166
158
108
153
174
Net Income
173
166
158
108
153
175
Net Income After Extraordinaries
173
166
158
108
153
175
Net Income Available to Common
173
166
158
108
153
175
EPS (Basic)
5.24
5.07
4.86
3.35
4.74
5.46
Basic Shares Outstanding
33
33
33
32
32
32
EPS (Diluted)
5.24
5.07
4.86
3.35
4.74
5.46
Diluted Shares Outstanding
33
33
33
32
32
32
EBITDA
318
330
285
225
305
336
Other Operating Expense
-
-
-
2
-
2
Non-Operating Interest Income
2
1
1
1
1
-
Minority Interest Expense
-
-
-
-
-
1

About Krka

View Profile
Address
Šmarješka cesta 6
Novo Mesto NM 8501
Slovenia
Employees -
Website http://www.krka.biz
Updated 07/08/2019
KRKA dd is a generic pharmaceutical company, which engages in the development, production, marketing, and sale of human and animal health products. It operates through the following geographical segments: European Union, South-East Europe, and Eastern Europe. The European Union segment includes all countries of the European Union.